Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

2.63
+0.01000.38%
Post-market: 2.59-0.0400-1.52%17:01 EDT
Volume:286.74K
Turnover:750.84K
Market Cap:39.76M
PE:-0.82
High:2.65
Open:2.65
Low:2.57
Close:2.62
52wk High:10.89
52wk Low:2.13
Shares:15.12M
Float Shares:9.60M
Volume Ratio:0.72
T/O Rate:2.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1959
EPS(LYR):-2.9824
ROE:-107.62%
ROA:-60.80%
PB:1.73
PE(LYR):-0.88

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cochlear (OtherCHEOF), CervoMed (CRVO) and Community Health (CYH)

TIPRANKS
·
Apr 24

CervoMed Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 23

Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed

TIPRANKS
·
Apr 23

CervoMed presents neflamapimod MRI data

TIPRANKS
·
Apr 22

CervoMed says neflamapimod boosts right basal forebrain volume in Lewy body dementia trial

Reuters
·
Apr 22

Roth MKM Remains a Buy on CervoMed (CRVO)

TIPRANKS
·
Apr 15

CervoMed Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 08

CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia

TIPRANKS
·
Apr 08

CervoMed says new Phase 2b MRI analysis supports neflamapimod slowing DLB progression

Reuters
·
Apr 07

CervoMed (CRVO) Gets a Buy from JonesTrading

TIPRANKS
·
Apr 07

CervoMed Posts Investor Presentation Under Regulation FD Disclosure

TIPRANKS
·
Mar 24

Cervomed Inc. Publishes Presentation Factsheet

Reuters
·
Mar 24

CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results

TIPRANKS
·
Mar 20

CervoMed Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed

Reuters
·
Mar 19

CervoMed’s neflamapimod shows efficacy in dementia with DLB

TIPRANKS
·
Mar 19

BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology

Reuters
·
Mar 19

CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL

Reuters
·
Mar 19

CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology

THOMSON REUTERS
·
Mar 19

CervoMed Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 18